Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in metastatic castration-resistant prostate cancer
NCT02881242Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2018
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Prostate Specific Antigen response rate at 12 weeks. Started Jan 2018; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02881242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881242.